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ABSTRACT 
Nanocarrier(s) are the potential carrier to revolutionize breast cancer diagnosis and therapy. Development of nanocarrier(s) loaded with 
drug, which is targeted to the cancer cell using ligand mediated drug delivery system. Some therapeutic nanocarrier(s) have b een 
approved for clinical use. There are only limited numbers of clinically approved nanocarriers that incorporate molecules to selectively 
bind and target cancer cells. Targeted drug delivery system is a unique approach for drug delivery to the appropriate site which is highly 
efficient, biocompatible, and non-immunogenic. The receptor mediated endocytosis is one of the targeting approaches specially for targeting 
anticancer drug to cancerous site. Breast cancer cells have overexpressed receptors like folate, transferrin, estrogen, human epidermal growth 
factor receptors (HER) which can be used for effective site specific drug delivery to cancerous cells using appropriate receptor s pecific ligand. 
This review examines some of the nanocarrier and discusses the challenges in translating basic research to the clin ic and the potential 
predictive markers of resistance to HER2-targeted therapies in breast cancer, novel drugs and drug combinations, including the promise of 
immunotherapy. 
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INTRODUCTION  
Cancer nanotechnology offers many opportunities in 
diagnosing and treating cancers due to their many possible 
and interesting interactions (Parodi et al., 2012, Tay et al., 
2016, Shi et al., 2011, Molinaro et al., 2011, Matsumoto et al., 
2016). Several nanoparticles (NPs) could induce endothelial 
leakiness (NanoEL)(Setyawati et al., 2013, Setyawati et al., 
2017, Tay et al., 2017, Wang et al., 2018, Qiu et al., 2017), 
cancer nanomedicines, considered to destroy the tumour cel 
(Ding et al., 2019, Li et al., 2018, Peng et al., 2018), may also 
unintentionally induce leakiness of the tumour vasculature, 
thereby lowering the barrier for intravasational entry of 
surviving cancer cells into the circulation. The growing 
evidence of nanomaterial can cause endothelial gaps that 
could be tens to hundreds of micrometres in width and large 
enough for whole cells to traverse (Setyawati et al., 2013, 
Setyawati et al., 2017, Setyawati et al., 2016), it is imperative 
then to establish whether cancer metastasis may be 
appreciably enhanced by nanomaterials. Moreover, these 
NPs have wide population exposure through processed 
healthcare products and vaccines (Yamashita et al., 2011, 
DeLoid et al., 2014, Hirai et al., 2016). This high population 
penetration may form an elevated basal level of NPs in 
cancer patients, thus extending the biological effects to 
situations where nanomedicine is not involved. In addition, 
there were possibly new sites of metastasis, suggesting that 
NPs or cancer nanomedicines may promote cellular entry to 
tissue sites previously inaccessible to the metastatic cells. 
The combination of these cellular events together with in 
vivo evidence will provide insights into how NPs could 
unintentionally promote cancer metastasis in a time- and 
concentration-dependent manner. The more intersecting 
approach starts with the discovery of the human epidermal 
growth factor receptor 2 (HER2) (King et al, 1985; Schechter 
et al, 1985), its association with poor prognosis in breast 
cancer (Slamon et al, 1987) and the potential of recombinant 
DNA technology to produce monoclonal antibodies 
developed as a promising strategies in the treatment of 
breast cancer. Monoclonal antibody trastuzumab (herceptin, 
Genentech, South San Francisco, CA, USA) used in oncology 
from non-specific chemotherapy to a molecularly targeted 
approach (Esteva, 2004). Trastuzumab binds domain IV of 
the extracellular component of the HER2 protein located 
close to the cell membrane, resulting in signal transduction 
blockade and prevention of HER2 cleavage. Addition of 
trastuzumab to conventional cytotoxic chemotherapy 
improved overall response rates (ORR), time to progression 
(TTP) and overall survival (OS) rates (Slamon et al, 2001). 
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Lapatinib, a tyrosine kinase inhibitor of EGFR and HER2 was 
found to be effective in combination with capecitabine in 
patients whose metastatic tumours were progressing on 
trastuzumab-based chemotherapy (Geyer et al, 2006). 
Pertuzumab (Perjeta, Genentech) is a humanised monoclonal 
antibody directed against domain II of the extracellular 
component of HER2, which is where receptor dimerisation 
occurs (Adams et al, 2006). Antibody–drug conjugates are 
another approach in oncology drug development. Ado-
trastuzumab-DM1 (T-DM1, Kadcyla) combines the HER2- 
targeted antitumor properties of trastuzumab with the 
antimicrotubule agent DM1 allowing preferential 
intracellular drug delivery to the HER2+ tumour cells. 
Trastuzumab, pertuzumab and T-DM1 can all induce 
antibody-dependent cellular cytotoxicity. Thus, HER2 
remains to be the most important predictive factor of 
response to HER2-targeted therapies (Seidman et al, 2001). 
The HER2+ breast cancer means if  the ratio of HER2/cep17 
is at least 2.0 or if the HER2 gene copy number is 46 (Wolff et 
al, 2013). Despite improvements in progression-free survival 
(PFS) and OS rates, HER2+ MBC remains an incurable 
disease and clinical research remains as important as ever. In 
this article we discuss the optimal sequencing of HER2-
targeted therapies in HER2+ MBC based on line of therapy. 
We discuss potential predictive markers of resistance to 
HER2-targeted therapies and review ongoing efforts to 
incorporate novel drugs and drug combinations, including 
the promise of immunotherapy. 
MOLECULAR MECHANISM OF RESISTANCE AND 
ONGOING CLINICAL TRIALS 
 The quantitative expression of human epidermal growth 
factor receptor 2 (HER-2), either in terms of protein or 
mRNA levels within the clinically-defined HER2-positive 
tumours seems to predict higher or lower probability of 
response, as shown repeatedly from pre-specified analyses 
of very influential prospective trials for examples; 
CLEOPATRA, EMILIA, NEO-SPHERE, NEO-ALTTO and 
TRYPHAENA) (Baselga et al, 2012; Gianni et al, 2012; 
Schneeweiss et al, 2013; Verma et al, 2012). Hyperactivation 
of the PI3K pathway by activating mutations or loss of PTEN 
expression has been associated with resistance to 
trastuzumab-based chemotherapy (Esteva et al, 2010; 
Nagata et al, 2004). Several studies shows that the PTEN loss 
may be a marker of trastuzumab resistance, patients who 
had been previously treated with trastuzumab and 
subsequently developed metastatic breast cancer, the 
metastatic tumours expressed lower levels of PTEN 
compared with primary tumours (Chandarlapaty et al, 
2012). Though, PTEN expression in primary breast cancer 
was not predictive of disease-free survival (DFS) or OS in 
adjuvant trastuzumab trials. Other proposed markers of 
trastuzumab resistance include a truncated form of HER2 
(p95), PIK3CA mutations (Berns et al, 2007; Esteva et al, 
2010), HER2/IGF-IR dimerisation (Nahta et al, 2005) and Src 
activation (Zhang et al, 2011). Molecular approaches provide 
target for rational drug development, still none of these 
markers have been validated in prospective clinical trials to 
exclude patients from HER2-directed therapies.  
NOVEL APPROACHES FOR THE TREATMENT OF 
BREAST CANCER 
1. Tyrosine Kinase Inhibitors 
Tyrosin kinase inhibitors used in breast cancer therapy. 
Afatinib is an orally active irreversible dual inhibitor of EGFR 
and HER2 receptors. In a phase II study, afatinib 
monotherapy in heavily pretreated HER2+ MBC 
demonstrated partial response (PR) in 4 patients (10% of 
41) and stable disease in 11 patients (37%of 41) (Lin et al, 
2012). Neratinib is an orally active irreversible inhibitor of 
EGFR, HER2 and HER4 receptors. In a phase II open-label 
clinical trial, 240 mg of oral neratinib was administered to 
trastuzumab pretreated (n=66) and a trastuzumab naı¨ve 
cohort (n=70). The ORR was 24% and 56%, respectively, and 
the most common grade 3 toxicity was diarrhoea. 
2. PI3K/Akt/mTOR Pathway Inhibitors 
In preclinical studies, the synergistic effect of mTOR inhibitor 
inhibitors with trastuzumab and have shown to cause 
complete regression of mouse HER2+ mammary tumours 
(Lu et al, 2007) In a phase I/II trial of trastuzumab combined 
with mTOR inhibitor everolimus for HER2+ MBC, PR was 
seen in 15% patients and s.d.46 months in 19% (Morrow et 
al, 2011). BOLERO-3 was a phase III trial comparing 
vinorelbine and trastuzumab alone or in combination with 
everolimus in 569 patents with HER2+ MBC resistant to 
trastuzumab. The preliminary findings of this study show 
significant prolongation in TTP (5.8 months vs 7 months, HR: 
0.78; 95% CI: 0.65–0.95; Po0.01) in the everolimus arm. 
Exploratory analysis of biomarkers in the BOLERO-3 trial 
suggests that the addition of everolimus to trastuzumab plus 
vinorelbine for HER2-positive advanced breast cancer may 
be most beneficial in patients with low PTEN or high pS6 
levels (Jerusalem et al, 2013). No clear benefit of everolimus 
was observed in patients with normal PTEN or low pS6 
levels. These data support the hypothesis that low PTEN 
expression is a marker of trastuzumab resistance (Nagata et 
al, 2004; Esteva et al, 2010). Subset analyses showed a larger 
benefit for the everolimus group in HER2+/HR_ tumours, 
compared with HER2+/HR+ tumours. This seems 
counterintuitive in view of the results of everolimus and 
exemestane in HR+ tumours (BOLERO-2. No treatment– 
biomarker interaction was reported between everolimus and 
PI3K mutations. Data from the Cancer Genome Atlas (TCGA-
Network, 2012) suggest that despite a similar incidence of 
PI3K mutation in HER2 enriched and luminal tumours, 
markers of pathway activations were differently expressed 
in these two subtypes in the presence of PI3K mutations. 
Several PI3 kinase inhibitors are under phase 1/2 stage of 
development. 
3. Heat Shock Protein 90 (HSP90) Inhibitor 
HSP90 inhibitors cause the proteosomal degradation of 
oncoproteins such as HER2. Additionally, p-95HER2, which is 
a truncated form of HER2 and also a major mechanism of 
trastuzumab resistance, has been shown to undergo 
degradation by HSP90 inhibitors. Tanespimycin has been 
evaluated in HER2+ MBC that had previously progressed 
trastuzumab in the phase II setting. The ORR was 22%, the 
clinical benefit rate (ORR and SD for at least 6 months) was 
59% and median PFS was 6 months (95% CI: 4–9 months). 
Another HSP90 inhibitor, ganetespib (STA- 9090), was tested 
as monotherapy in a phase II setting (Jhaveri et al, 2014). 
Using Simon stage design, in the first stage of this design, the 
study did not meet the primary endpoint of ORR. Modest 
activity was noted in heavily pretreated, trastuzumab-
refractory patients. Based on the preclinical data that shows 
synergistic activity for combining HSP90 inhibitors with 
taxanes. 
4. Other Targeted Strategies 
The processes of tumor cell growth, angiogenesis and 
metastases associated with the KD019 is a small molecule 
that simultaneously blocks the tyrosine kinase of EGFR, 
HER2, Src and the vascular endothelial growth factor 
receptor 2 (VEGFR2). A phase I study of KD019 plus 
trastuzumab in HER2 overexpressed or amplified MBC is 
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ongoing for patients who have received two or more prior 
anti-HER2-directed therapies (Jhaveri et al (2014), 
Perlmutter Cancer Center at NYU Langone). It has been 
demonstrated that cross-talk between IGF-1R and HER2 as 
well as IGF mediated phosphorylation of HER2 results in 
trastuzumab resistance (Nahta et al, 2005, 2006), providing 
merit to exploring IGF-1R inhibitors such as Cixotumumab in 
clinical trials. Preclinical studies have shown upregulation of 
VEGF in HER2 overexpressed breast cancers, and the phase 2 
study of trastuzumab and bevacizumab combination in 
HER2+ MBC was promising. However, bevacizumab, a 
monoclonal antibody against VEGF-A receptor, failed to 
improve PFS when combined with trastuzumab and 
docetaxel in a phase 3 trial compared with the non-
bevacizumab arm (Gianni et al, 2013). One of the 
mechanisms of action of trastuzumab is thought to be 
induction of ADCC. It has been demonstrated that higher 
percentage of tumour infiltrating lymphocytes is associated 
with better response to trastuzumab in both adjuvant (Loi et 
al, 2013) and neoadjuvant setting. In correlative preclinical 
studies, higher PD-1 (programmed death-1), a T-cell 
checkpoint ligand expression, was associated with greater 
trastuzumab benefit. The negative regulator of T-cell 
mediated immune response is PD-1, so antibodies blocking 
PD-1 and its ligand PD-L1 enhance the T-cell mediated 
immune response. Trastuzumab may modulate tumour 
microenvironment by inhibiting tumour-mediated 
immunosuppression via factors like PD-1 (Stagg et al, 2011). 
Combining trastuzumab with anti-PD-1 and anti-PD-L1 
antibodies showed greater tumour regression in mouse 
models of HER2+ mammary tumours. Therefore, there seems 
to be merit in exploring the impact of combining 
trastuzumab with inhibitors of negative T-cell regulation, 
such as anti-CTLA4 antibody, anti-PD-1 or anti-PDL-1, in 
HER2+ MBC. One peptide-based vaccine that merits special 
mention is the E75 vaccine derived from the extracellular 
domain of HER2 receptor. When compared with the 
unvaccinated arm, E75 was found to decrease recurrence 
rates when administered in the adjuvant setting for node 
positive HER2+ breast cancer (DFS rates at 22 months: 
85.7% vs 59.8%) (Peoples et al, 2005). 
CONCLUSIONS 
Targeted drug delivery system is an inherent technique for 
the delivery of drugs to the appropriate sites for effective 
treatment. Apart from these, it also includes various ligand 
mediated drugs targeting with the help of varieties of 
nanocarriers which increase the therapeutic effect on target 
site with less side effects. The quantitative expression of 
human epidermal growth factor receptor 2 (HER-2), either in 
terms of protein or mRNA levels within the clinically-defined 
HER2-positive tumor. Lack of thoroughly validated 
predictive biomarkers has been one of the major hurdles to 
stratify breast cancer patients and to monitor tumor 
progression and response to the therapy. Investigations in 
clinic and preclinical models have provided some molecular 
and cellular mechanisms for the above challenges.  
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